Rh Illness

In "Rh affliction," more properly known as erythroblastosis fetalis, the erythrocytes of the fetus are destroyed during the pregnancy of Rh− mothers carrying their second (or afterward) Rh+ fetus.

From: The Immune Response , 2006

Transplantation

In Primer to the Allowed Response (Second Edition), 2014

Rh illness can be prevented by passively immunizing an Rh − woman with an anti-Rh antibody preparation early during her showtime pregnancy and again soon subsequently the nascence of her first kid. The exogenous anti-Rh antibodies bind to the Rh antigen on whatsoever fetal RBCs that accessed the maternal circulation during birth, clearing them earlier they can interact with naïve anti-Rh B cells in the female parent. About no retentiveness anti-Rh B cells are generated, so that if the fetus in the adjacent pregnancy is Rh+, the gamble of fetal harm is reduced. As insurance, Rh− women are given anti-Rh antibodies throughout and after subsequent pregnancies.

Read full chapter

URL:

https://www.sciencedirect.com/scientific discipline/article/pii/B9780123852458000170

Pregnancy

Tolu Oyelowo DC , in Mosby's Guide to Women's Health, 2007

Management.

Rh disease is increasingly rare because Rh-negative mothers are given the drug RhoGAM at 28 weeks of gestation and immediately postpartum, and this prevents the formation of antibodies in an Rh-negative female parent. Rh-positive mothers do not have to worry, even if the begetter is Rh negative. Rh claret typing and testing currently are performed routinely at the commencement visit. If the mother is Rh positive, there is no crusade for business organization. If, even so, the mother is Rh negative, the begetter should be checked. If he also is Rh negative, there is no business concern, because the infant will be Rh negative and there is no take a chance of antibiotic production. If the father is Rh positive, there is susceptibility for disease and the test will be repeated to check for antibodies in the sixth and eighth months and at delivery. Amniocentesis may be performed to bank check for bilirubin, which is released into the amniotic fluid if and when the fetal blood cells are cleaved downwardly by maternal Rh antibodies.

Read full affiliate

URL:

https://www.sciencedirect.com/scientific discipline/article/pii/B9780323046015500290

Neutropenia

Katherine A. Janeway , in Comprehensive Pediatric Hospital Medicine, 2007

Alloimmune Neonatal Neutropenia

Alloimmune neonatal neutropenia, like to Rh disease in the newborn, is caused by transplacental passage of maternal immunoglobulin G antibodies directed against fetal cells (neutrophils) begetting paternally derived antigens. This causes an immune-mediated neutropenia that is present at nascence. Similar Rh affliction, alloimmune neonatal neutropenia usually affects the children of multiparous women, likely considering maternal exposure to paternal neutrophil antigens occurs during prior pregnancy or childbirth. Neutropenia is typically severe and resolves when maternal antibodies terminate to be present in the child'southward serum, usually between 3 and 28 weeks of life. Risk of infection is increased, but infections tend to exist balmy, with the skin being afflicted most unremarkably; however, more severe infections such every bit pneumonia take been reported. 14 Delayed separation of the umbilical cord has been described. 15 Diagnosis is made either clinically or by identifying antineutrophil antibodies in both the mother and the infant. As with autoimmune neutropenia, testing for antineutrophil antibodies is difficult and may non yield a positive outcome, even when antibodies are present. Likewise, bone marrow biopsy shows a hypercellular marrow with a decreased number of neutrophils, suggestive of premature destruction of mature forms rather than bone marrow failure. Treatment with G-CSF, 15 steroids, or IVIG should exist reserved for neutropenic patients with infections that are non responsive to antimicrobial therapy.

Read full chapter

URL:

https://www.sciencedirect.com/science/article/pii/B9780323030045501228

Rhesus and Other Fetomaternal Incompatibilities

M. Lau , in Reference Module in Biomedical Sciences, 2014

Prenatal Rh Genotyping

Until recently, two approaches were used to identify the fetus, which is at risk for Rh disease. These approaches include fetal blood sampling or series amniocentesis. Fetal blood sampling carries a 1–two% risk of fetal loss and a xl% risk of fetomaternal hemorrhage. Serial amniocentesis is less accurate because information technology is unable to distinguish between an RhD negative fetus from a mildly affected Rh-D positive fetus. Information technology also exposes the mother to multiple invasive procedures as well as increases her risk for Rh sensitization. Now, the cloning and sequencing of the Rh C/c, E/east, and D cDNAs have allowed for Rh genotyping of the fetus through the use of a small amount of Deoxyribonucleic acid from sources such as amniocytes, chorionic villi, and fetal cells/complimentary fetal DNA in the maternal circulation.

Read full chapter

URL:

https://www.sciencedirect.com/science/article/pii/B978012801238305546X

Immunotherapy

Anahid Jewett , Han-Ching Tseng , in Pharmacology and Therapeutics for Dentistry (Seventh Edition), 2017

Rho(D) immunoglobulin

Rho(D) immunoglobulin represents a special case in which passive immunization is used to induce specific immunosuppression for the prevention of Rh affliction . Rh disease occurs when an Rh-negative woman—one whose red blood cells practise non contain the Rho(D) antigen—becomes sensitized to the antigen past exposure to the blood of her Rh-positive fetus. On subsequent pregnancies, the female parent'south anti-Rh antibody passes through the placenta and causes massive destruction of fetal erythrocytes, resulting in hemolytic disease of the newborn.

The injection of anti-Rh antibiotic into Rh-negative mothers who will give nascence to Rh-positive infants is effective in preventing the disorder. The goal of treatment is to preclude mothers from generating anti-Rho(D) antibodies. Loftier titers of specific antibiotic confronting an antigen specifically inhibit the immune response to that antigen, simply the mechanism may be more than circuitous than elementary binding of the antigenic stimulus. The injection of anti-Rho(D) antibodies may induce the mother to generate a set of antibodies against the variable domains of the injected antibodies. This 2nd fix of anti-idiotypic antibodies may impede the interaction of B cells with Rh antigen, cause B cell inactivation or death, or neutralize anti-Rho(D)–specific antibodies as they are generated. Such idiotypic–anti-idiotypic inhibitory effects have been shown in laboratory animals. Alternatively, anti-Rho(D) antibiotic may lead to rapid clearance of fetal ruddy claret cells from the mother'southward circulation by liver macrophages, which would prevent the elicitation of chronic inflammatory reactions necessary for antibody responses.

Antiserum to the Rh antigen is produced in Rh-negative male person volunteers. The γ-globulin fraction containing anti-Rh antibody, in the form of Rho(D) immunoglobulin (human), must be given within hours of parturition because the fetal erythrocytes carrying the Rh antigen enter the mother's body at this time and induce the immune response that would cause bug in subsequent pregnancies. This specific immunosuppressive treatment has been very successful in preventing Rh disease, and it is now used routinely.

Read full chapter

URL:

https://www.sciencedirect.com/science/article/pii/B9780323393072000357

Anemia During the Neonatal Menstruum

Philip Lanzkowsky One thousand.B., Ch.B., M.D., Sc.D. (honoris causa), F.R.C.P., D.C.H., F.A.A.P. , in Manual of Pediatric Hematology and Oncology (Fifth Edition), 2011

Antenatal

Patients should exist screened at their first antenatal visit for Rh and non-Rh antibodies. Figure ii-2 shows a schema of the antenatal management of Rh disease. If an immune antibody is detected in the mother's serum, proper management includes the following:

Effigy ii-2. Schema of Antenatal Management of Rh Disease.

*Percutaneous umbilical vein claret sampling.

**Amniotic fluid analysis is less reliable prior to the 26th week of gestation and PUBS is recommended. IUIVT, Intrauterine intravenous transfusion.
•

Past obstetric history and outcome of previous pregnancies. History of prior claret transfusions

•

Blood group and indirect antiglobulin examination (to determine the presence and titer of irregular antibodies). Most irregular antibodies tin crusade erythroblastosis fetalis; therefore, screening of maternal serum is important. Titers should be determined at diverse weeks of gestation (Effigy 2-2). The frequency depends on the initial or subsequent ascent in titers. Theoretically, whatsoever claret group antigen (with the exception of Lewis and I, which are non present on fetal erythrocytes) may cause erythroblastosis fetalis. Anti-Lea, Leb, Yard, H, P, S and I are IgM antibodies and rarely, if ever, cause erythroblastosis fetalis and demand not cause concern

•

Zygosity of the father: If the mother is Rh negative and the father is Rh positive, the father's zygosity becomes critical. If he is homozygous, all his future children will be Rh positive. If the begetter is heterozygous, at that place is a 50% chance that the fetus will exist Rh negative and unaffected. The Rh genotype can exist accurately determined past the use of polymerase chain reaction (PCR) of chorionic villus tissue, amniotic cells and fetal blood when the father is heterozygous or his zygosity is unknown. Mothers with fetuses establish to be Rh D negative (dd) can be reassured and further serologic testing and invasive procedures can be avoided. Fetal zygosity can thus exist determined by molecular genetic techniques. Fetal Rh D genotyping can be performed rapidly on maternal plasma in the 2nd trimester of pregnancy without invading the fetomaternal apportionment. This is performed by extracting DNA from maternal plasma and analyzing information technology for the Rh D cistron with a fluorescent-based PCR examination sensitive enough to observe the Rh D gene in a unmarried jail cell. The advantage of this exam is that neither the mother nor the fetus is exposed to the risks of amniocentesis or chorionic villus sampling

•

Exam of the amniotic fluid for spectrophotometric analysis of bilirubin. By obstetric history and antibiotic titer are indications for serial amniocentesis and spectrophotometric analyses of amniotic fluid to determine the condition of the fetus. Amniotic fluid analysis correlates well with the hemoglobin and hematocrit at nativity (requals;0.ix) just does not predict whether the fetus volition require an exchange transfusion subsequently birth. The following are indications for amniocentesis:

•

History of previous Rh affliction severe enough to require an substitution transfusion or to cause stillbirth

•

Maternal titer of anti-D, anti-c, or anti-Kell (or other irregular antibodies) of i:8 to ane:64 or greater past indirect antiglobulin test or albumin titration and depending on previous history. An assessment of the optical density deviation at 450   µm (ΔOD450) at a given gestational age permits reasonable prediction of the fetal effect (Figure 2-iii). Determination of the appropriate handling depends on the ΔOD450 of the amniotic fluid, the results of the fetal biophysical profile scoring and the assessment of the presence or absence of fetal hydrops (seens on ultrasound) and amniotic phospholipid determinations (lung profile).*

Figure 2-3. Assessment of Fetal Prognosis by the Methods of Liley and of Freda. Liley's Method of Prediction.

Zone 1A: Condition desperate, immediate commitment or intrauterine transfusion required, depending on gestational age. Zone 1B: Hemoglobin less than 8   g/dl, delivery or intrauterine transfusion urgent, depending on gestational age. Zone 2A: Hemoglobin viii–10   g/dl, delivery at 36–37 weeks. Zone 2B: Hemoglobin 11.0–xiii.ix   grand/dl, commitment at 37–39 weeks. Zone iii: Not anemic, deliver at term. Freda's method of prediction: Zone 4+: Fetal death imminent, immediate delivery or intrauterine transfusion, depending on gestational age. Zone 3+: Fetus in jeopardy, decease within iii weeks, delivery or intrauterine transfusion as soon as possible, depending on gestational historic period. Zone two+: Fetal survival for at least 7–x days, echo amniocentesis indicated, possible indication for intrauterine transfusion, depending on gestational age. Zone 1+: Fetus in no immediate danger.

 From: Robertson JG. Evaluation of the reported methods of interpreting spectrophotometric tracings of amniotic fluid analysis in Rhesus isoimmunization. Am J Obstet Gynecol 1966;95:120, with permission.
Features of Lung Profile Immature Fetus Mature Fetus
Lecithin/sphingomyelin ratio <2.0 >2.0
Acetone-precipitable fraction <45% >50%
Phosphatidylinositol Absent Present (small-scale amounts)
Phosphatidylglycerol Absent Nowadays (prominent)

If the amniotic fluid optical density departure at 450   µm (ΔOD450) indicates a severely affected fetus and phospholipid estimations signal lung maturity, the infant should be delivered. If the ΔOD450 indicates a severely affected fetus and the phospholipid estimations betoken marked immaturity, maternal plasmapheresis and/or intrauterine intravascular transfusion (IUIVT) should be carried out. IUIVT has many advantages over intraperitoneal fetal transfusions and is the process of choice. This decision is made in conjunction with the biophysical contour score.

Intensive maternal plasmapheresis antenatally using a continuous-flow jail cell separator tin significantly reduce Rh antibiotic levels, reduce fetal hemolysis and improve fetal survival in those mothers conveying highly sensitized Rh-positive fetuses. This procedure together with IUIVT should exist carried out when a high antibody titer exists early before a fourth dimension that the infant could be safely delivered.

If the take a chance of perinatal death resulting from complications of prematurity is loftier, then an IUIVT should be carried out. Percutaneously, the umbilical vein is used for blood sampling (PUBS) and venous access and permits a fetal transfusion via the intravascular route (IUIVT). With the availability of high-resolution ultrasound guidance, a fine (20 gauge) needle is inserted directly into the umbilical string, either at the insertion site into the placenta or into a costless loop of string. This allows the same blood sampling as is available postnatally in the neonate. Temporary paralysis of the fetus with the use of pancuronium bromide (Pavulon) facilitates the procedure, which may be applied to fetuses from 18 weeks' gestation until the gestational historic period when fetal lung maturity is confirmed. The interval betwixt procedures ranges from 1 to three weeks.

Blood used for IUIVT should be cytomegalovirus-negative packed RBCs with a packed cell volume of 85–88%. Cells should be fresh, leukocyte-depleted and irradiated to foreclose the low chance of graft-versus-host disease. The employ of kell antigen-negative blood is optimal, if available.

The risks of IUIVT include:

•

Fetal loss (ii%)

•

Premature labor and rupture of membranes

•

Chorioamnionitis

•

Fetal bradycardia

•

Cord hematoma or laceration

•

Fetomaternal hemorrhage.

The overall survival rate is 88%. Intraperitoneal transfusion can be performed in addition to IUIVT to increase the corporeality of claret transfused and to extend the interval between transfusions.

Modern neonatal care, including attention to metabolic, nutritional and ventilatory needs and the use of bogus surfactant insufflation, makes successful before delivery possible. The need for IUIVT and intraperitoneal transfusion is rarely indicated.

Read total chapter

URL:

https://www.sciencedirect.com/science/commodity/pii/B9780123751546000021

Perinatal Alloantibody Disorders – Neonatal Alloimmune Thrombocytopenia/Hemolytic Affliction of the Fetus and Newborn

J.B. Bussel , J.Grand. Despotovic , in Reference Module in Biomedical Sciences, 2014

Abstract

This article will overview hemolytic illness of the fetus and newborn (HDFN) and alloimmune thrombocytopenia (AIT). HDFN is the all-time known course of alloimmune anemia and is besides known as Rh disease. It is caused by incompatibility in red prison cell antigens between the parents, resulting in maternal sensitization and antibiotic development against the 'strange' (paternal) antigen. The sensitization process is believed to involve the transport of fetal cells across the placenta into the mother resulting in antibiotic made to the incompatible antigen on those cells. A like pathophysiology involving platelets defines AIT platelet disorder. There are many similarities just many of import differences between these two well-known disorders. This article will advisedly describe both HDFN and AIT, consider similarities and differences between them, and review epidemiology, diagnosis, pathophysiology, and treatment of each.

Read full chapter

URL:

https://world wide web.sciencedirect.com/scientific discipline/article/pii/B9780128012383000775

Laboratory Aids for Diagnosis of Neonatal Sepsis

Geoffrey A. Weinberg , Carl T. D'Angio , in Infectious Diseases of the Fetus and Newborn (Seventh Edition), 2011

Haptoglobin

Haptoglobin is an αii -glycoprotein that reacts with gratis hemoglobin to grade a circuitous, which is removed by the reticuloendothelial system. Gestational age, neonatal asphyxia, gender, and hemolytic ABO/Rh disease have no significant influence on haptoglobin levels in cord blood or during the postnatal period; however, elevated levels normally persist for several days later exchange transfusion, probably as a outcome of passive transfer of blood with adult concentrations of the poly peptide. Inaccuracies related to phenotypic variants of haptoglobin, although seen when levels are measured by radial immunodiffusion, have not presented a problem when concentrations are determined by laser nephelometry. Clinical studies have raised serious doubts about the reliability of haptoglobin concentrations in the prediction of neonatal sepsis [ 20,24,121,157,158].

Read full chapter

URL:

https://www.sciencedirect.com/science/article/pii/B9781416064008000365

Breastmilk & Breastfeeding Jaundice

Cynthia R. Howard MD, MPH, FAAP , in Pediatric Clinical Advisor (2nd Edition), 2007

Laboratory Tests

•

Bilirubin—direct and indirect

○

Indirect hyperbilirubinemia is present in both breastfeeding and breastmilk jaundice.

•

Mother and babe claret type (to rule out ABO affliction), directly and indirect Coombs test

•

Maternal prenatal antibiotic screen (to dominion out Rh disease and other blood group sensitization)

•

Syphilis serology of cord blood

•

Urine for reducing substances (to dominion out galactosemia)

•

Hemoglobin, blood smear, reticulocyte count (to rule out polycythemia and hemolysis, as well as ruddy blood cell membrane abnormalities)

•

Consideration of assay (if indicated by history) to rule out enzyme deficiencies such as glucose–half dozen‐phosphate dehydrogenase deficiencies (G6PD) and pyruvate kinase

•

Consideration of serum electrolytes if infant appears dehydrated

○

Potential hypernatremia, elevated blood urea nitrogen (BUN), and creatinine in breastfeeding jaundice

•

Consideration of need to evaluate for sepsis

•

Consideration of need to evaluate electrolytes on maternal milk

○

Sodium may exist elevated in breastfeeding jaundice if milk volume has decreased because of poor removal (involution of glandular tissue) or in cases of insufficient glandular tissue (normal seven   mEq/L or 16   mg/dL)

Read full chapter

URL:

https://www.sciencedirect.com/science/commodity/pii/B9780323035064100471

Thrombocytopenia

Sam Volchenboum , in Comprehensive Pediatric Hospital Medicine, 2007

Neonatal Thrombocytopenia

Presentation and Evaluation

Neonatal immune thrombocytopenia is a relatively common, potentially devastating disorder that necessitates prompt intervention once diagnosed. Dissimilar older children with very low platelet counts who are at only modest risk of intracranial bleeding, the incidence of intracranial hemorrhage in neonates with thrombocytopenia is higher than 20%. 8 Therefore, if diagnosed in utero, cesarean department is often recommended to avoid head trauma during vaginal delivery. A fetus tin be exposed to antiplatelet antibodies in 2 main ways. Kickoff, a mother with ITP can pass her antiplatelet antibodies to her child, every bit evidenced by low platelet counts in both the mother and baby. This illness is unremarkably self-limited, and the child should respond to the aforementioned therapies as described earlier for ITP, mainly IVIG and steroids. Series platelet counts need to be obtained to document a durable response to therapy.

A more serious disorder occurs when the mother's immune system recognizes paternal antigens on fetal platelets and makes immunoglobulin G (IgG) that crosses the placenta and binds to fetal platelets, thereby hastening their devastation. This disorder is known equally neonatal alloimmune thrombocytopenia (NAIT). It is similar to Rh disease of the newborn, but unlike Rh illness, antigenic exposure can occur early in gestation and pb to an affected offspring with the first pregnancy. Generalized petechiae can develop within minutes of birth. Intracranial hemorrhage can occur, sometimes in utero, and result in fetal demise. Considering future pregnancies are clearly at risk, high-take chances obstetric intendance for the affected mother is essential.

The diagnosis of NAIT tin can often exist fabricated by carefully considering the history, concrete examination, and laboratory findings. Unlike neonatal ITP secondary to maternal ITP, the female parent'due south platelet count should be normal in NAIT. Furthermore, the baby should have no evidence of other systemic illness. If a bone marrow report is performed, there should be increased numbers of megakaryocytes, as would be expected when the cause is increased destruction of platelets.

Treatment

Every bit mentioned, thrombocytopenia secondary to maternal ITP is self-limited and usually requires no therapy. However, NAIT requires immediate treatment. The ideal treatment is transfusion of platelets known to non exhibit the offending antigen on their surface. Fortunately, a source of these antigen-negative platelets exists in the mother of the kid. Importantly, the mother'southward platelets should be done earlier transfusion (to remove plasma containing maternal antibodies) and irradiated (to eliminate the risk for transfusion-associated graft-versus-host disease). If maternal platelets are non available, the claret banking company may exist able to obtain platelets defective the platelet antibody. Random donor platelets may be used, but the benefit will probably be very short lived, and they should be reserved for cases of life- or limb-threatening haemorrhage. Intravenous gamma globulin and steroids are good options to maintain acceptable platelet counts until resolution of the process (typically several weeks). Additionally, a head ultrasound should be performed during the acute phase of the illness to evaluate for intracranial hemorrhage. Finally, once a baby is plant to take NAIT, every effort should exist made to determine the platelet genotypes of the mother and father because this will be important both for verifying the diagnosis of NAIT and for genetic counseling and obstetric care in future pregnancies.

Read total affiliate

URL:

https://world wide web.sciencedirect.com/scientific discipline/article/pii/B978032303004550123X